Saredutant

Source: Wikipedia, the free encyclopedia.
Saredutant
Clinical data
ATC code
  • none
Identifiers
  • N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)- 2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide
JSmol)
  • Clc1ccc(cc1Cl)[C@H](CCN3CCC(c2ccccc2)(NC(=O)C)CC3)CN(C(=O)c4ccccc4)C
  • InChI=1S/C31H35Cl2N3O2/c1-23(37)34-31(27-11-7-4-8-12-27)16-19-36(20-17-31)18-15-26(25-13-14-28(32)29(33)21-25)22-35(2)30(38)24-9-5-3-6-10-24/h3-14,21,26H,15-20,22H2,1-2H3,(H,34,37)/t26-/m1/s1 checkY
  • Key:PGKXDIMONUAMFR-AREMUKBSSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Saredutant (SR-48,968) is a

phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.[2]

See also

References

  1. PMID 22776916
    .
  2. ^ "Letter to the stockholders of Sanofi-Aventis" (PDF). May 2009. Archived from the original (PDF) on 21 December 2010.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Saredutant&oldid=1188193639"